Shuttle Pharmaceuticals appoints Dr. Bette Jacobs to Board, fills vacancy

Shuttle Pharmaceuticals Holdings, Inc.

Appointed Dr. Bette Jacobs as independent director to fill vacancy left by William Adkins, effective Oct 28, 2022.
Dr. Jacobs will serve on Audit Committee and Nominating and Corporate Governance Committee.
Compensation includes $25,000 annual cash and $100,000 in RSUs vesting over three years.
Board amended bylaws to reduce director term from three years to one year.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

William Adkins

Director

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2022-10-28
Successor: Bette Jacobs
Filed: November 1, 2022, 7:59 PM ET

seat vacated by William Adkins, an independent director, whose term of service ended effective as of October 28, 2022.

Appointed

Bette Jacobs

Director

SHPH · Shuttle Pharmaceuticals Holdings, Inc.

Effective: 2022-10-28
Filed: November 1, 2022, 7:59 PM ET

On October 28, 2022, the board of directors (the “Board”) of Shuttle Pharmaceuticals Holdings, Inc., a Delaware Corporation (the “Company”), based upon the recommendation of the Board’s Nominating and Corporate Governance Committee, approved the appointment of Bette Jacobs, Ph.D. to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

William Adkins departed as Director at Shuttle Pharmaceuticals Holdings, Inc..

Action: vacated
Role: Director

Exact text from the filing

seat vacated by William Adkins, an independent director, whose term of service ended effective as of October 28, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bette Jacobs was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 28, 2022, the board of directors (the “Board”) of Shuttle Pharmaceuticals Holdings, Inc., a Delaware Corporation (the “Company”), based upon the recommendation of the Board’s Nominating and Corporate Governance Committee, approved the appointment of Bette Jacobs, Ph.D. to the Board.

View on SEC.gov

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-030066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.